

# British National Formulary Bnf 65

## Introduction to the British National Formulary BNF 65

The **British National Formulary BNF 65** stands as a cornerstone in the daily practice of healthcare professionals across the United Kingdom. Published in March 2013 as the 65th edition of this essential reference work, it provides authoritative, up-to-date information on the selection, prescribing, dispensing, and administration of medicines. For doctors, pharmacists, nurses, and other prescribers, the BNF is not merely a book; it is a trusted clinical tool that guides safe and effective pharmacotherapy. This article explores the significance of the BNF 65, its structure, its role in clinical decision-making, and why even today its legacy continues to influence prescribing practices.

### Understanding the British National Formulary

The British National Formulary is published jointly by the British Medical Association (BMA) and the Royal Pharmaceutical Society (RPS). Each semi-annual edition consolidates the latest evidence-based guidance, drug monographs, and prescribing information. The BNF 65 is part of this long-running series that ensures clinicians have access to verified, concise data about licensed medicines used in the UK. The formulary covers all major therapeutic areas, from cardiovascular and respiratory medicine to psychiatry and palliative care.

What makes the **British National Formulary BNF 65** particularly valuable is its rigorous editorial process. Expert committees of clinicians, pharmacists, and pharmacologists review new clinical trials, safety alerts, changes in drug licensing, and updated national guidelines before each edition is published. This ensures that the BNF reflects current best practice, making it a reliable resource for both common and rare conditions.

### Key Features of the BNF 65 Edition

While each BNF edition builds on its predecessors, BNF 65 introduced several updates that reflected the evolving landscape of UK healthcare. Some notable features include:

- **New chemical entities:** The 65th edition included monographs for drugs newly licensed in the UK, such as newer anticoagulants and targeted

cancer therapies.

- **Updated guidance on antimicrobials:** In response to growing antimicrobial resistance, the BNF 65 reinforced recommendations for prudent prescribing, including narrower spectrum antibiotics when appropriate.
- **Prescribing caution updates:** Safety warnings from the Medicines and Healthcare products Regulatory Agency (MHRA) were incorporated, such as contraindications and interactions for statins and non-steroidal anti-inflammatory drugs (NSAIDs).
- **Palliative care and paediatric dosing:** Special sections were refined to improve clarity for vulnerable populations, reflecting the increasing emphasis on personalised medicine.
- **Practical prescribing tools:** The appendices provided quick-reference charts for renal impairment dose adjustments, liver disease, and pregnancy categories – all critical for safe prescribing.

## Structure and Organisation of the BNF 65

---

The **British National Formulary BNF 65** is organised to facilitate rapid access to information. It opens with preliminary pages containing a table of contents, list of proprietary and non-proprietary names, and general guidance on prescribing. The main body is divided into chapters by therapeutic category (e.g., cardiovascular system, central nervous system, infections). Each chapter begins with a summary of drug classes, followed by individual monographs.

Each monograph includes:

- **Drug name** (generic and selected brand names)
- **Indications** and licensed uses
- **Dosage** for adults and children (with weight-based calculations where necessary)
- **Contraindications**, cautions, and important interactions
- **Side effects** ranked by frequency
- **Pregnancy and breastfeeding** information
- **Cost** bands (A, B, C, D) to support cost-effective prescribing

Beyond monographs, the BNF 65 includes essential guidelines on emergency treatment of poisoning, prescribing in renal and hepatic impairment, drug interactions, and prescribing in the elderly. These sections are often the first port of call for clinicians managing complex patients.

### Why BNF 65 Remains Relevant

Although subsequent editions of the BNF have been published, the **British National Formulary BNF 65** holds historical importance and is still used in some contexts. For example, medical libraries, training programmes, and regulatory bodies sometimes refer to archived editions for teaching or medicolegal purposes. The 65th edition captures a specific moment in UK pharmacotherapy – a time when new classes of drugs like direct oral anticoagulants (DOACs) were entering mainstream practice and the emphasis on rational prescribing was intensifying.

Moreover, studying older editions helps practitioners understand how drug guidance evolves. By comparing BNF 65 with the current edition, one can trace changes in recommended doses, withdrawn drugs, and shifts in clinical evidence. This perspective is invaluable for clinical audit, research, and historical analysis of prescribing trends.

### Role of the BNF in Clinical Practice

---

For the healthcare professional, the **British National Formulary BNF 65** is more than a reference – it is a decision-support tool. When a doctor writes a prescription for a patient, they must consider not only the appropriate drug and dose but also potential interactions with other medications, the patient's renal function, and any contraindicated conditions. The BNF provides this information in a structured, evidence-based format that can be accessed quickly during a consultation.

Pharmacists rely on the BNF to verify prescriptions and to counsel patients on correct usage. Nurses and non-medical prescribers use it as a training resource and a day-to-day guide. In many NHS trusts, the BNF is referenced in local prescribing policies and formularies, reinforcing its role as a national standard.

### How the BNF 65 Improved Patient Safety

One of the most critical contributions of any BNF edition is the improvement of patient safety. The **British National Formulary BNF 65** included explicit warnings about high-risk medications such as warfarin, insulin, and methotrexate. The “Prescribing in Children” section highlighted weight-based dosing and common errors. Additionally, the inclusion of a dedicated section on drug interactions helped reduce the incidence of adverse drug events.

The BNF also promotes a culture of rational prescribing. By presenting information neutrally and without commercial bias, it guides prescribers toward

choosing the most effective and safest treatment, often with cost implications considered. This aligns with the principles of the NHS Constitution and the duty of care owed to patients.

## Digital Evolution: From Print to Online

---

The BNF 65 was released in print format, but its content also fed into digital platforms such as the BNF website and mobile apps (which launched later). Today, most clinicians access the BNF online or via smartphone, but the print edition remains valuable for those without constant internet access or who prefer a physical copy. The **British National Formulary BNF 65** represents one of the last editions where print was the primary medium for many users.

Nonetheless, the core principles of the BNF – accuracy, impartiality, and usability – have remained consistent through its transition to digital. The 65th edition can be considered a milestone in that digital transition, as readers began to expect hyperlinked cross-references and searchable text.

### Using BNF 65 for Educational Purposes

Medical, pharmacy, and nursing students are often introduced to the BNF early in their training. The **British National Formulary BNF 65** is a valuable teaching resource because it provides real-world prescribing information. Students learn to navigate the structure, interpret drug monographs, and apply the information to clinical scenarios. Many educators use case studies based on BNF 65 content to teach clinical pharmacology and therapeutics.

Furthermore, the BNF's style of presenting information – concise bullet points, clear hierarchies – teaches students how to synthesise complex data. It also emphasises the importance of checking multiple parameters (dose, interactions, contraindications) before prescribing, a habit that enhances patient safety.

## The Global Perspective: BNF vs. Other Formularies

---

While the **British National Formulary BNF 65** is tailored to the UK, it is also used internationally in countries where UK prescribing practices are followed. It differs from formularies like the *Drug Facts and Comparisons* (United States) or the *Martindale: The Complete Drug Reference* in its emphasis on UK-specific licensing, NHS prescribing guidance, and cost bands. For practitioners working in the UK, it remains the gold standard.

The BNF 65 also influenced the development of other national formularies, including the *Australian Medicines Handbook* and the *New Zealand Formulary*, demonstrating its global impact.

## Criticisms and Limitations of BNF 65

---

No reference work is perfect. Some critics of the BNF 65 noted that it could be slow to incorporate the very latest evidence, given its six-month publication cycle. Urgent safety alerts sometimes arrived after the edition was printed. Additionally, the print format meant that users had to manually check for updates via the BNF website or supplements. However, these limitations are inherent to any printed medical formulary.

Another limitation is that the BNF does not include unlicensed or off-label uses of drugs, which are sometimes necessary in specialised areas such as paediatrics or oncology. Clinicians must rely on additional resources for such cases.

## The Legacy of the BNF 65

---

Today, the **British National Formulary BNF 65** may be considered a historical document, but its legacy endures. It set a standard for clarity, conciseness, and clinical relevance that successive editions have upheld. It was used by thousands of clinicians to make millions of prescribing decisions. For researchers studying pharmacoepidemiology or the history of drug therapy in the UK, BNF 65 provides a snapshot of therapeutic practice in 2013.

Moreover, the editorial policies established in that edition – transparent conflict-of-interest statements, systematic review of evidence, and inclusion of patient safety warnings – continue to shape the BNF today. The 65th edition helped build the trust that healthcare professionals place in the formulary.

## How to Access the BNF 65

---

For those interested in consulting the **British National Formulary BNF 65**, copies may be available in medical libraries, second-hand bookstores, or online archives. The Royal Pharmaceutical Society and the BMA maintain historical collections. Some academic institutions digitised older editions for internal use. However, for current clinical practice, healthcare professionals are advised to use the latest BNF (updated every six months) or the BNF for Children (BNFC) for paediatric prescribing.

## Alternative Resources

If the BNF 65 is needed for reference but unavailable, alternatives include the current BNF online, the *British National Formulary for Children*, and *Martindale*. These resources build on the foundations laid by earlier editions.

## Conclusion

---

The **British National Formulary BNF 65** was a pivotal edition in the history of UK prescribing practice. It provided clinicians with a trusted, evidence-based resource for making informed decisions about drug therapy. Although superseded by newer editions, its contribution to patient safety, rational prescribing, and medical education remains significant. Whether used as a training tool, a historical artefact, or a reference for quality assurance, BNF 65 exemplifies the high standards of the British National Formulary series. For any healthcare professional interested in the evolution of pharmacotherapy, studying this edition offers valuable insights that remain relevant today.